Immunoglobulin G1 [351-alanine,386-alanine,387-alanine] anti-(human epidermal growth factor receptor HER2) (human-Mus musculus monoclonal IMM2902 ?1-chain), disulfide with 1-125-signal regulatory protein ? [80-alanine] (human isoform 4 variant) fusion protein with peptide linker ((GGGGS)3) fusion protein with human-Mus musculus monoclonal IMM2902 ?-chain, dimer
Advanced Gastric Cancer
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.monoclonal_antibodyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 89/ 100
Competitive context
282 Active assets in the Advanced Gastric Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Rivoceranib Jiangsu Hansoh Pharmaceutical Co., Ltd. | Phase 4 | BBB |
FLUOROURACILUM I-Mab Biopharma US Limited | Phase 4 | BB |
Eloxatin Qilu Pharmaceutical Co., Ltd. | Phase 3 | BB |
Pembrolizumab Eikon Therapeutics | Phase 3 | BB |
Epirubicin Rondo Therapeutics | Phase 3 | BB |
View all 50 →
Same molecule, other indications
Immunoglobulin G1 [351-alanine,386-alanine,387-alanine] anti-(human epidermal growth factor receptor HER2) (human-Mus musculus monoclonal IMM2902 ?1-chain), disulfide with 1-125-signal regulatory protein ? [80-alanine] (human isoform 4 variant) fusion protein with peptide linker ((GGGGS)3) fusion protein with human-Mus musculus monoclonal IMM2902 ?-chain, dimer is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →